PointState Capital’s Boston Scientific BSX Stock Holding History

PointState Capital’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-151,000	Closed	-$6.41M	–	82
2021 Q4	$6.41M	Sell	151,000 -19,000	-11%	-$798K	0.11%	77
2021 Q3	$7.38M	Buy	+170,000	New	+$7.52M	0.12%	94
2017 Q2	–	Sell	-913,800	Closed	-$22.7M	–	142
2017 Q1	$22.7M	Buy	+913,800	New	+$22.2M	0.24%	70

Other funds holding BSX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Bollard Group Boston, Massachusetts $3.29B AUM 4.86% 1-Year Est. Return

PointState Capital's BSX Position: Q1 2022 in Review

PointState Capital sold out of Boston Scientific (BSX) in Q1 2022, closing a stake of 151,000 shares — an estimated $6.41M sold.

PointState Capital first reported a position in BSX in Q1 2017 and held it in 3 quarters. The position peaked at $22.7M in Q1 2017. 904 funds tracked by Wall St. Rank hold BSX as of Q1 2022.

PointState Capital reported no remaining Boston Scientific position as of Q1 2022 after selling out during the quarter.
PointState Capital sold 151,000 Boston Scientific shares in Q1 2022, an estimated $6.41M.
PointState Capital first reported a position in Boston Scientific in Q1 2017 and held it in 3 quarters.
PointState Capital's Boston Scientific position peaked at $22.7M in Q1 2017.
904 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2022.

Based on PointState Capital's 13F filing for Q1 2022, filed 13 May 2022.